Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011
Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002
Fosfomycin for pseudomonas related exacerbations of cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008
Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017 Year: 2018
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Long term treatment with azithromycin in chronic respiratory infections with pseudomonas aeruginosa Source: Eur Respir J 2006; 28: Suppl. 50, 558s Year: 2006
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003
Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasisSource: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001
Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006
Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017 Year: 2017